Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422723/
https://www.ncbi.nlm.nih.gov/pubmed/28512412
http://dx.doi.org/10.1159/000461576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422723/
https://www.ncbi.nlm.nih.gov/pubmed/28512412
http://dx.doi.org/10.1159/000461576

Ejemplares similares